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OBJECTIVES The objective of this study was to evaluate the relation between apolipoprotein A-IV
(apoA-IV) plasma concentrations and coronary artery disease (CAD).
BACKGROUND Experimental in vitro and in vivo studies favor apoA-IV to be protective against the
development of atherosclerosis. Mice that overexpress either human or mouse apoA-IV
demonstrated a significant reduction of aortic atherosclerotic lesions compared with control
mice. Data on apoA-IV plasma concentrations and CAD in humans are lacking.
METHODS We determined in two independent case-control studies of a Caucasian and an Asian Indian
population whether apoA-IV plasma concentrations are related to the presence of angio-
graphically assessed CAD.
RESULTS Plasma apoA-IV levels were significantly lower in 114 male Caucasian subjects with
angiographically defined CAD when compared with 114 age-adjusted male controls (10.2 6
3.8 mg/dL vs. 15.1 6 4.0 mg/dL, p , 0.001). Logistic regression analysis indicated that the
association between apoA-IV levels and CAD was independent of the high-density
lipoprotein cholesterol and triglyceride concentrations. The inverse relationship between
plasma levels of apoA-IV and the presence of CAD was confirmed in an independent sample
of 68 male Asian Indians with angiographically documented CAD and 68 age-matched
controls.
CONCLUSIONS The results of this cross-sectional study demonstrate for the first time an association between
low apoA-IV concentrations and CAD in humans and suggest that apoA-IV may play an
antiatherogenic role in humans. (J Am Coll Cardiol 2000;36:751–7) © 2000 by the
American College of Cardiology
Human apolipoprotein A-IV (apoA-IV) is a 46 kDa gly-
coprotein (1) that is almost exclusively produced in intesti-
nal enterocytes and secreted into the lymph as a structural
protein of chylomicrons (2). The mean plasma level of
apoA-IV is about 15 mg/dL. The distribution of apoA-IV
among plasma lipoproteins varies depending on the plasma
fractionation method. In the fasting state the majority of
apoA-IV circulates in plasma as part of a lipid-poor, small
high-density lipoprotein (HDL)-like particle that does not
contain apolipoprotein A-I (apoA-I) (3,4). The remaining
moiety of apoA-IV is associated with apolipoprotein A-I
(apoA-I) containing HDL particles of larger size, and its
levels vary over a wide range in the literature (3,5,6).
The physiological function of apoA-IV is not clear. It was
postulated to be involved in fat absorption (7), but recently
this hypothesis has been challenged by findings in trans-
genic mice that express high levels of human apoA-IV in
the intestine and mice in which the gene has been inacti-
vated (8,9). Both strains of genetically modified mice absorb
lipids normally and are phenotypically indistinguishable
from wild type mice.
Intravenous apoA-IV infusion to rats resulted in a reduc-
tion of food intake, therefore suggesting it may function as
a satiety factor (10). However, A-IV knockout mice failed
to reveal any abnormalities in their feeding behavior (9).
Numerous in vitro studies suggest that apoA-IV partici-
pates in several steps of the reverse cholesterol transport
pathway, which removes cholesterol from peripheral cells
and transports it to the liver or steroidogenic organs where
cholesterol can be metabolized to bile acids and hormones,
respectively. Apolipoprotein A-IV binds to peripheral cells,
promotes cholesterol efflux and enhances the formation of
small HDL particles (11,12) by activating lecithin:
cholesterol acyltransferase (13,14). In addition, apoA-IV
may participate in the binding and uptake of HDL by
hepatocytes (15). Moreover, apoA-IV modulates the acti-
vation of lipoprotein lipase (16) and the cholesteryl ester
transfer protein (CETP)-mediated transfer of cholesteryl
esters from HDL to low-density lipoprotein (LDL) in
tissue culture studies (17). Taken together, these in vitro
functions suggest that apoA-IV may represent an anti-
atherogenic factor.
In vivo studies in animals support this antiatherogenic
role for apoA-IV. Fat-fed mice that overexpress either
human (18) or mouse apoA-IV (19) demonstrated a signif-
icant reduction of aortic atherosclerotic lesions compared
with control mice. Atherosclerosis was even inhibited by
overexpression of human apoA-IV in apoE-deficient mice,
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which are hyperlipidemic and develop severe atherosclerosis
even on chow diets (18).
In this study we aimed to investigate whether the findings
in transgenic mice have a clinical correlative in humans. We,
therefore, measured apoA-IV plasma concentrations in two
different ethnic populations of patients with angiographi-
cally verified coronary artery disease (CAD) and compared
them with those in controls of the same population.
METHODS
Caucasian study population. A total of 114 consecutive
male subjects who underwent coronary angiography and had
coronary stenosis of $50% of the luminal diameter in at
least one coronary artery were included in the study. These
patients were recruited from the geographical area of Tyrol,
Austria. The mean age was 60 6 10 years, and 43 had
single-vessel disease; 33 had double-vessel disease, and 38
had a stenotic lesion in three or more vessels. Sixty-two of
the 114 patients had suffered a coronary event (myocardial
infarction, aortocoronary bypass of percutaneous translumi-
nal coronary angioplasty) at least six weeks and up to 24
years before the coronary angiography. Patients were com-
pared with 114 male controls with a mean age of 53 6 8
years who were recruited in 1997 during a follow-up project
of the Mu¨nster Heart Study (PROCAM) from one of the
PROCAM study centers in Germany (20). Apolipoprotein
A-IV levels in these controls were identical with the levels
obtained in a previous group of blood donors (21) recruited
from the same geographical area as the patients of this study
and similar to controls from Northern, Middle and South-
ern Europe in the European Atherosclerosis Research Study
(EARS) (22). Subjects with renal impairment (serum cre-
atinine .1.5 mg/dL or a macroalbuminuria) (6,21) were
excluded from the analysis. Patients and controls gave
informed consent to the investigation.
Indian study population. We also analyzed the apoA-IV
plasma concentrations in 68 male patients from India with
entry criteria as mentioned above and 68 age-matched male
controls from the same geographical area as patients. The
mean age was 52 6 8 years, and 22 of them showed a
single-vessel disease; 16 had double-vessel disease, and 30
had stenosis of three or more arteries.
Samples and laboratory procedures. Venous blood was
obtained in tubes containing ethylenediamine tetraacetate
(EDTA) one to three days before coronary angiography
after an overnight fasting period. The plasma was isolated
and frozen at 270°C before analysis (on average 6 to 12
weeks after withdrawal) (23). Storing samples under those
conditions is without any consequence on the measured
values within a storage period of six months (23).
Plasma apoA-IV concentrations were determined using
an enzyme-linked immunosorbent assay that employs
affinity-purified rabbit antihuman apoA-IV polyclonal an-
tiserum as the capture antibody and the same antibody
coupled with horseradish peroxidase as detection antibody
(23,24). Plasma with known content of apoA-IV (standard-
ized with purified apoA-IV after phenylalanin quantifica-
tion by high pressure liquid chromatography) served as
calibration standard. Intraassay and interassay coefficients of
variation of this assay are 4.5% and 6.6%, respectively (23).
Samples from the patients and controls were analyzed in
duplicate within one series in a blinded fashion and after a
similar time of sample storage at 270°C.
Total cholesterol, HDL cholesterol and triglycerides
were measured using kits from Boehringer Mannheim
(Mannheim, Germany). Measurements were made on
microtitre plates as previously described (23). Low-
density lipoprotein cholesterol was calculated with the
Friedewald formula.
Statistical methods. Because controls were on average
seven years younger than patients in the Caucasian study
population, we adjusted total, HDL and LDL cholesterol as
well as triglycerides using linear regression analysis. No
correlation was observed between apoA-IV and age neither
in patients (r 5 0.09, p 5 0.30) nor in controls (r 5 0.06,
p 5 0.54). Therefore, unadjusted apoA-IV concentrations
were used for the analysis. Continuous variables were
compared between patients and controls by unpaired t test
or by the Mann-Whitney U test (triglycerides). Power
calculation revealed a power of 99% at a significance level of
p , 0.05 to detect a difference in apoA-IV plasma concen-
tration of 2.4 mg/dL between patients and controls in the
Caucasian study population and of 2.8 mg/dL in the Asian
Indian population.
Categorial variables were compared in the Caucasian
study group using Pearson’s chi-square test. Correlation
coefficients between apoA-IV and total HDL and LDL
cholesterol were calculated by the method of Pearson.
Because of their non-Gaussian frequency distribution, cor-
relations of triglycerides were calculated according to Spear-
man. Logistic regression analysis was performed to evaluate
whether apoA-IV concentrations are associated with CAD
independently of HDL cholesterol and triglycerides. Odds
ratios (OR) as an approximation of the true relative risk of
having CAD were calculated from the regression coeffi-
cients while adjustment was made for other variables.
Statistical analysis was performed with Statistical Package
for the Social Sciences (SPSS) for Windows 9.0 (SPSS Inc.,
Chicago, Illinois). A p value ,0.05 was used as level of
significance for hypothesis testing.
Abbreviations and Acronyms
apoA-IV 5 apolipoprotein A-IV
apoA-I 5 apolipoprotein A-I
CAD 5 coronary artery disease
EARS 5 European Atherosclerosis Research Study
HDL 5 high-density lipoprotein
LDL 5 low-density lipoprotein
OR 5 odds ratio
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RESULTS
Table 1 shows the clinical characteristics as well as the
differences of cardiovascular risk factors between Caucasian
patients with CAD and their controls. The subjects with
CAD had markedly lower apoA-IV concentrations than
controls (10.2 6 3.8 mg/dl vs. 15.1 6 4.0 mg/dL, p ,
0.001). The frequency distribution of apoA-IV concentra-
tions in patients and controls is shown in panel A of Figure
1. The distribution was shifted to lower concentrations in
the Caucasian subjects with CAD, so a markedly higher
percentage of the subjects with CAD had low plasma
apoA-IV concentrations. Concentrations of plasma HDL
cholesterol were significantly lower and triglycerides higher
in the patients than they were in controls. Plasma levels of
total and LDL cholesterol levels were lower in the CAD
group, probably because a large percentage of the patients
(64%) were on lipid-lowering medication.
Correlation of apoA-IV with other variables. We exam-
ined the relationship between the plasma apoA-IV concen-
trations and the other variables that differed significantly in
frequency between patients and controls. Subjects receiving
antihypertensive drugs had similar plasma apoA-IV concen-
trations than those without these medications in both
patients (10.2 6 3.7 mg/dL vs. 9.9 6 4.2 mg/dL) and
controls (15.4 6 4.2 mg/dL vs. 15.0 6 4.0 mg/dL). Patients
who received lipid-lowering drugs had similar apoA-IV
concentrations compared with those without (10.1 6 3.9
mg/dL vs. 10.3 6 3.6 mg/dL). Furthermore, apoA-IV
concentrations in patients who had already suffered a major
coronary event previously did not differ from those without
an event (10.0 6 3.7 mg/dL vs. 10.3 6 3.9 mg/dL).
Plasma apoA-IV concentrations correlated slightly with
HDL cholesterol in both the patient and control groups
(Fig. 2), but no significant relationship was seen between
apoA-IV levels and total cholesterol and LDL cholesterol or
triglyceride concentrations.
Association of apoA-IV, HDL cholesterol and triglycer-
ides with CAD. Figure 3 presents the odds of being a
patient as an approximation of the relative risk in case of low
or high plasma concentrations of apoA-IV, HDL choles-
terol or triglycerides. The median levels of these variables







Age (yrs) 53 6 8 60 6 10 0.001
Body mass index (kg/m2) 27.5 6 3.2 (26.1 2 28.1) 26.4 6 3.8 (25.7 2 27.1) 0.022
Diabetes mellitus (%) 7.9 12.3 0.27
Current smokers (%) 29 27 0.77
Antihypertensive medication (%) 16 81 0.001
Lipid-lowering drugs (%) 0 62 0.001
Results of coronary angiography (n %)
Single-vessel disease 43 (38) –
Double-vessel disease 33 (29) –
Three or more vessel disease 38 (33) –
ApoA-IV (mg/dL) 15.1 6 4.0 (14.3–15.8) 10.2 6 3.8 (9.5–10.9) 0.001
Total cholesterol (mg/dL*) 217 6 40 (209–224) 194 6 46 (186–203) 0.001
HDL cholesterol (mg/dL*) 40.7 6 8.8 (39.1–42.4) 34.0 6 11.3 (31.9–36.1) 0.001
LDL cholesterol (mg/dL*) 144 6 36 (137–150) 120 6 39 (113–127) 0.001
Triglycerides (mg/dL*) 162 6 105 (143–182) 201 6 132 (176–225) 0.005
Median 135 164
Values are presented as mean 6 SD (95% confidence interval), unless otherwise stated. CAD 5 coronary artery disease; HDL 5
high-density lipoprotein; LDL 5 low-density lipoprotein.
*Adjusted for age.
Figure 1. Distribution of apolipoprotein A-IV (apoA-IV) plasma concen-
trations in patients with coronary artery disease and controls. Panel A
shows the results of 114 Caucasian male patients and 114 male controls.
Panel B describes the apoA-IV distribution in 68 male Asian Indian
patients and 68 age-matched male controls.
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from the control group were used as categorization cut-
points. Having low compared with high plasma HDL
cholesterol concentrations increased the probability of being
a patient about 2.3 and 2.5 times in the group with high and
low apoA-IV plasma concentrations, respectively. On the
other hand, having low apoA-IV concentrations increased
the odds about six-fold in both groups with high and low
HDL cholesterol concentrations (Fig. 3, panel A). Very
similar ORs were observed for apoA-IV and triglyceride
concentrations (Fig. 3, panel B). This clearly shows that the
association of apoA-IV with CAD is independent from
HDL cholesterol or triglycerides but additive to their
association with CAD.
Logistic regression analysis. We further examined the
association of apoA-IV with CAD using a logistic regres-
sion analysis (Table 2). All three variables, apoA-IV, HDL
cholesterol and triglycerides, significantly predicted CAD in
univariate analysis. High-density lipoprotein cholesterol and
triglycerides, however, predicted CAD with a much lower
probability than apoA-IV concentrations. Multivariate
analysis showed that the association of apoA-IV with CAD
was independent of HDL cholesterol and triglycerides for
two reasons: first, no large differences in the ORs of
apoA-IV were seen between univariate analysis and multi-
variate analysis including either HDL cholesterol (model 1)
or triglycerides (model 2). Each 2 mg/dL decrease of
apoA-IV increased the odds for being a patient between
79% and 93% depending on the model. The inclusion of
HDL cholesterol or triglycerides in the model did not
increase the frequency of subjects of about 75% correctly
classified as patient or control. Second, the introduction of
an interaction term between apoA-IV and HDL cholesterol
or triglycerides did not contribute to the model. Repeating
the analysis excluding patients who already had a history of
CAD or those taking lipid-lowering drugs revealed a similar
Figure 3. Odds ratio (OR) and 95% confidence interval (CI) as an
approximation of the relative risk a patient with coronary artery disease in
case of low or high plasma concentrations of apolipoprotein A-IV
(apoA-IV) and HDL cholesterol (panel A) and in case of low or high
plasma concentrations of apoA-IV and triglycerides (TG) (panel B). The
median levels of these variables from the control group were used as
categorization cutpoints. Arrows provide the relative increase of the odds.
Figure 2. Correlation between plasma concentrations of apolipoprotein
A-IV (apoA-IV) and high-density lipoprotein (HDL) cholesterol in
Caucasian controls (panel A) and Caucasian patients (panel B).
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OR of 1.88 (1.42 to 2.48), which was close to the results
obtained in the whole patient group as presented in Table 2.
Asian Indian study population. Finally, we confirmed the
association of apoA-IV with CAD in an independent ethnic
population. We compared apoA-IV levels of 68 male Asian
Indian patients with CAD to those of age-matched male
controls from the same geographical area. Patients showed
significantly lower apoA-IV concentrations compared with
controls (7.6 6 3.5 mg/dL vs. 10.4 6 4.1 mg/dL, p ,
0.001) with a markedly different distribution of apoA-IV
concentrations (Fig. 1, panel B).
DISCUSSION
Novel findings. The physiological role of apoA-IV in
lipoprotein metabolism is still not clear. Both in vitro and in
vivo studies suggest that apoA-IV is antiatherogenic due to
its involvement in reverse cholesterol transport. In this study
we provide compelling evidence of a relationship between
low apoA-IV concentrations and CAD in two different
ethnic populations. Patients with CAD had 30% lower
apoA-IV concentrations when compared with their respec-
tive controls. This difference in apoA-IV levels between
patients and controls was even seen in the Asian Indian
study population, which is characterized by markedly lower
concentrations of apoA-IV when compared with Cauca-
sians. These relative differences between the ethnic groups is
most probably explained by the different diet, which is
known to influence apoA-IV concentrations (25).
Previous studies. Our data are in contrast with two previ-
ous studies, which are different in study design, and the
populations investigated. First, the EARS described similar
apoA-IV concentrations in children whose fathers had
suffered a myocardial infarction before age 55 years and
controls (22). This might be explained by a recent investi-
gation in 119 nuclear families using a variance component
model, which favored an environmental over a genetic
model (26). Even if genetic factors determine apoA-IV
concentrations partially, it might take major efforts to detect
significant differences of apoA-IV concentrations in chil-
dren of fathers with myocardial infarction and age-matched
controls without a family history of coronary heart disease.
An association of apoA-IV with myocardial infarction in
fathers is expected to be diluted in offsprings due to the
genetic contribution from the mothers’ side. The other
study investigated patients with noninsulin-dependent dia-
betes mellitus and described significantly higher apoA-IV
concentrations in patients compared with those without
macrovascular complications (CAD, cerebral vascular dis-
ease and peripheral arteriopathy) (27). One explanation for
this discrepancy to our data is the increased prevalence of
microalbuminuria and the concomitant renal impairment in
diabetic patients with macrovascular complications. Unfor-
tunately, the authors did not provide detailed data on renal
function in their patients (27). A slight impairment of renal
function with creatinine concentrations .1.5 mg/dL with
or without microalbuminuria is already associated with a
dramatic increase in apoA-IV concentrations (Kronenberg
et al., unpublished observation 2000). Because diabetic
patients with macrovascular complications are more likely to
have renal disease than diabetic patients without vascular
disease, high levels of apoA-IV in diabetic patients with
macrovascular complications may simply reflect their im-
paired renal function. For this reason we excluded patients
and controls with renal impairment from our analysis.
Studies that investigated the relationship between genetic
polymorphisms of apoA-IV and CAD found no associa-
tions (22,28–30). This is not surprising since these poly-
morphisms do not impact significantly on lipoprotein me-
tabolism or apoA-IV concentrations (22,28,29,31–33). The
correlation of apoA-IV plasma levels with HDL cholesterol
Table 2. Logistic Regression Analysis Investigating the Predictive Value of ApoA-IV, HDL
Cholesterol and Triglyceride Concentrations for CAD




ApoA-IV (22 mg/dL) 0.628 0.088 50.6 1.89 (1.59–2.22) 0.0001
HDL cholesterol (25 mg/
dL)
0.346 0.076 20.6 1.41 (1.22–1.64) 0.0001
In-transformed triglycerides* 0.727 0.258 7.9 2.07 (1.25–3.43) 0.0049
Multivariate analysis: model 1
ApoA-IV (22 mg/dL) 0.587 0.091 42.0 1.79 (1.52–2.13) 0.0001
HDL cholesterol (25 mg/
dL)
0.194 0.081 5.7 1.22 (1.03–1.43) 0.0171
Interaction term† – – – – 0.86
Multivariate analysis: model 2
ApoA-IV (22 mg/dL) 0.651 0.092 50.2 1.93 (1.61–2.27) 0.0001
In-transformed triglycerides* 0.920 0.301 9.0 2.46 (1.37–4.44) 0.0027
Interaction term† – – – – 0.87
*No linear increment can be provided because triglycerides were logarithmically transformed before inclusion into the model;
†interaction term of the two variables included in the model.
ApoA-IV 5 apolipoprotein A-IV; CAD 5 coronary artery disease; CI 5 confidence interval; HDL 5 high-density
lipoprotein; OR 5 odds ratio.
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observed in this study (Fig. 2) was also found in the EARS
study (22). The correlation was slightly stronger in CAD
patients (r 5 0.28) than it was in controls (r 5 0.22). Since
only about 8% (r2 5 0.08) and 5% (r2 5 0.05), respectively,
of the variance was explained by the other variable, apoA-IV
and HDL cholesterol were independently associated with
CAD in the logistic regression analysis (Table 2). This may
reflect the observation from in vitro experiments that
apoA-IV forms distinct lipid-poor and apoA-I-free parti-
cles, which are very effective mediators of cholesterol efflux
(3,4) and are not assessed by the measurement of HDL
cholesterol.
Possible pathophysiological mechanisms. One explana-
tion of the inverse association of apoA-IV with CAD is its
involvement in several steps of the reverse cholesterol
transport. Low apoA-IV concentrations might result in a
decreased efflux of cholesterol from peripheral cells, de-
creased esterification of free cholesterol as well as a dimin-
ished CETP-mediated transfer of cholesterylesters from
HDL to LDL as shown in cell culture studies (3,4,11–
17,34). A promotion of lipid-induced atherosclerotic
changes might be the consequence. Support for this hypoth-
esis comes from experiments in mice overexpressing apoA-
IV. High-density lipoprotein-sized lipoproteins of these
animals promoted cholesterol efflux from cholesterol-loaded
human monocytes more efficiently than HDL from control
animals. Furthermore, plasma from these apoA-IV overex-
pressing animals exhibited a higher endogenous cholesterol
esterification rate (19). Another potentially antiatherogenic
effect of apoA-IV is its endogenous antioxidative quality
described recently; apoA-IV significantly inhibited the
copper-mediated oxidation of lymph and LDL and the
macrophage-mediated oxidation of fasting lymph, and it
increased the time of conjugated diene-formation (35).
Study limitations. A high percentage of the Caucasian
patients had already suffered a cardiovascular event at the
time of evaluation, and, therefore, 62% were already under
antilipemic treatment. This treatment, however, has prob-
ably not caused the lower apoA-IV concentrations in
patients since treated and untreated patients showed similar
concentrations, and the logistic regression analysis excluding
treated patients revealed similar results. Moreover, a similar
relative concentration difference in apoA-IV was observed
in the Indian study population whose CAD patients were
not under antilipemic treatment. Because of the influence of
antilipemic treatment on other lipoproteins, an extensive
multivariate modeling in the statistical analysis including
total and LDL cholesterol as well as triglyceride concentra-
tions is not possible. We, therefore, confined our calculation
to the question of whether apoA-IV concentrations predict
CAD independently of HDL cholesterol and triglyceride
concentrations.
Since apoA-IV plasma concentrations are significantly
lower in women than they are in men and are influenced by
hormonal status and use of oral contraceptives (22), we
confined our study to men. This allowed a better controlling
for confounders but necessitates investigating the observed
association in a future study in women.
We had no reliable possibility to control for physical
activity and diet, two possible confounders of apoA-IV
concentrations (22,25). Moderate and hard exercise levels in
men tended to increase apoA-IV levels slightly in the EARS
study although the highest apoA-IV levels were measured in
subjects with a low level of activity (22). Since a lower
activity level is more often expected in patients with CAD
and since this association is only weak in men, we do not
expect a considerable influence on our results. Diet, on the
other hand, is expected to have a stronger influence on
apoA-IV levels. Weinberg et al. (25) described apoA-IV to
be positively correlated with the percent of total daily caloric
intake ingested by fat. However, this might have diminished
rather than increased the difference in apoA-IV levels
between patients and controls of our study because patients
with CAD are expected to have a higher fat intake than
control subjects (36). Nevertheless, we found similar results
when we excluded all patients from the analysis who had
already suffered a major coronary event and who might,
therefore, have changed their diet.
Conclusions. Low apoA-IV levels are associated with
CAD, and this association is independent of triglycerides
and HDL cholesterol concentrations. This cross-sectional
study cannot answer the question whether low apoA-IV
concentrations are a cause or a consequence of CAD. A
causal relationship is, however, likely in view of the inhib-
itory effect of transgenic apoA-IV expression on atheroscle-
rosis in mice, and the in vitro findings pointing to the role
of apoA-IV in the antiatherogenic reverse cholesterol trans-
port. Presently, apoA-IV concentrations can at least serve as
a valuable diagnostic marker for CAD.
Acknowledgments
We wish to thank Dr. Steven C. Hunt (Cardiovascular
Genetics, University of Utah, Salt Lake City) for helpful
comments and critical reading of the manuscript.
Reprint requests and correspondence: Dr. Florian Kronenberg,
Institute of Medical Biology and Human Genetics, University of
Innsbruck, Scho¨pfstrasse 41, A-6020 Innsbruck, Austria. E-mail:
Florian.Kronenberg@uibk.ac.at.
REFERENCES
1. Utermann G, Beisiegel U. Apolipoprotein A-IV: a protein occurring
in human mesenteric lymph chylomicrons and free in plasma. Isolation
and quantification. Eur J Biochem 1979;99:333–43.
2. Green PHR, Glickman RM, Riley JW, Qinet E. Human apolipopro-
tein A-IV. Intestinal origin and distribution in plasma. J Clin Invest
1980;65:911–9.
3. Duverger N, Ghalim N, Ailhaud G, Steinmetz A, Fruchart J-C,
Castro G. Characterization of apoA-IV containing lipoprotein parti-
cles isolated from human plasma and interstitial fluid. Arterioscler
Thromb 1993;13:126–32.
4. Von Eckardstein A, Huang Y, Wu S, et al. Lipoproteins containing
apolipoprotein A-IV but not apolipoprotein A-I take up and esterify
756 Kronenberg et al. JACC Vol. 36, No. 3, 2000
ApoA-IV and CAD September 2000:751–7
cell-derived cholesterol in plasma. Arterioscler Thromb Vasc Biol
1995;15:1755–63.
5. Lagrost P, Gambert P, Boquillon M, Lallemant C. Evidence for high
density lipoproteins as the major apolipoprotein A-IV containing
fraction in normal human serum. J Lipid Res 1989;30:1525–34.
6. Dieplinger H, Lobentanz E-M, Ko¨nig P, et al. Plasma apolipoprotein
A-IV metabolism in patients with chronic renal disease. Eur J Clin
Invest 1992;22:166–74.
7. Apfelbaum TF, Davidson NO, Glickman RM. Apolipoprotein A-IV
synthesis in rat intestine: regulation by dietary triglyceride. Am J
Physiol 1987;252:G662–6.
8. Aalto-Seta¨la¨ K, Bisgaier CL, Ho A, et al. Intestinal expression of
human apolipoprotein A-IV in transgenic mice fails to influence
dietary lipid absorption or feeding behavior. J Clin Invest 1994;93:
1776–86.
9. Weinstock PH, Bisgaier CL, Hayek T, et al. Decreased HDL
cholesterol levels but normal lipid absorption, growth and feeding
behavior in apolipoprotein A-IV knockout mice. J Lipid Res 1997;38:
1782–94.
10. Fujimoto K, Cardelli JA, Tso P. Increased apolipoprotein A-IV in rat
mesenteric lymph after lipid meal acts as a physiological signal for
satiation. Am J Physiol 1992;262:G1002–6.
11. Stein O, Stein Y, Lefevre M, Roheim PS. The role of apolipoprotein
A-IV in reverse cholesterol transport studied with cultured cells and
liposomes derived from another analog of phosphatidylcholine. Bio-
chim Biophys Acta 1986;878:7–13.
12. Steinmetz A, Barbaras R, Ghalim N, Clavey V, Fruchart J-C, Ailhaud
G. Human apolipoprotein A-IV binds to apolipoprotein A-I/A-II
receptor sites and promotes cholesterol efflux from adipose cells. J Biol
Chem 1990;265:7859–63.
13. Steinmetz A, Utermann G. Activation of lecithin:cholesterol acyl-
transferase by human apolipoprotein A-IV. J Biol Chem 1985;260:
2258–64.
14. Chen CH, Albers JJ. Activation of lecithin:cholesterol acyltransferase
by apolipoproteins E-2, E-3 and A-IV isolated from human plasma.
Biochim Biophys Acta 1985;836:279–85.
15. Dvorin E, Gorder NL, Benson DM, Gotto AM Jr. Apolipoprotein
A-IV. A determinant for binding and uptake of high density lipopro-
teins by rat hepatocytes. J Biol Chem 1986;261:15714–8.
16. Goldberg IJ, Scheraldi CA, Yacoub LK, Saxena U, Bisgaier CL.
Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by
apolipoprotein A-IV. J Biol Chem 1990;265:4266–72.
17. Guyard-Dangremont V, Lagrost L, Gambert P. Comparative effects
of purified apolipoproteins A-I, A-II and A-IV on cholesteryl ester
transfer protein activity. J Lipid Res 1994;35:982–92.
18. Duverger N, Tremp G, Caillaud JM, et al. Protection against
atherogenesis in mice mediated by human apolipoprotein A-IV.
Science 1996;273:966–8.
19. Cohen RD, Castellani LW, Qiao JH, Van Lenten BJ, Lusis AJ, Reue
K. Reduced aortic lesions and elevated high density lipoprotein levels
in transgenic mice overexpressing mouse apolipoprotein A-IV. J Clin
Invest 1997;99:1906–16.
20. Assmann G, Schulte H, Von Eckardstein A. Hypertriglyceridemia
and elevated lipoprotein(a) are risk factors for major coronary events in
middle-aged men. Am J Cardiol 1996;77:1179–84.
21. Kronenberg F, Ko¨nig P, Neyer U, et al. Multicenter study of
lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-
stage renal disease treated by hemodialysis or continuous ambulatory
peritoneal dialysis. J Am Soc Nephrol 1995;6:110–20.
22. Ehnholm C, Tenkanen H, Deknijff P, et al. Genetic polymorphism of
apolipoprotein A-IV in five different regions of Europe. Relations to
plasma lipoproteins and to history of myocardial infarction: the EARS
study. Atherosclerosis 1994;107:229–38.
23. Kronenberg F, Lobentanz E-M, Ko¨nig P, Utermann G, Dieplinger
H. Effect of sample storage on the measurement of lipoprotein(a),
apolipoproteins B and A-IV, total and high-density lipoprotein
cholesterol and triglycerides. J Lipid Res 1994;35:1318–28.
24. Rosseneu M, Michiels G, Dekeersgieter W, et al. Human apolipopro-
tein A-IV quantitation by sandwich enzyme linked immunosorbent
assay. Clin Chem 1988;34:739–43.
25. Weinberg RB, Dantzker C, Patton CS. Sensitivity of serum apoli-
poprotein A-IV levels to changes in dietary fat content. Gastroenter-
ology 1990;98:17–24.
26. Zaiou M, Visvikis S, Gueguen R, et al. Sources of variability of human
plasma apolipoprotein A-IV levels and relationships with lipid metab-
olism. Genet Epidemiol 1994;11:101–14.
27. Verge`s BL, Lagrost L, Vaillant G, et al. Macrovascular disease is
associated with increased plasma apolipoprotein A-IV levels in
NIDDM. Diabetes 1997;46:125–32.
28. Tenkanen H, Koskinen P, Metso J, et al. A novel polymorphism of
apolipoprotein A-IV is the result of an asparagine to serine substitu-
tion at residue 127. Biochim Biophys Acta 1992;1138:27–33.
29. Bai H, Saku K, Liu R, Oribe Y, Yamamoto K, Arakawa K. Polymor-
phism of the apolipoprotein A-IV gene and its significance in lipid
metabolism and coronary heart disease in a Japanese population. Eur
J Clin Invest 1996;26:1115–24.
30. Von Eckardstein A, Heinrich J, Funke H, et al. Glutamine/histidine
polymorphism in apo A-IV affects plasma concentrations of lipopro-
tein(a) and fibrin split products in coronary heart disease patients.
Arterioscler Thromb 1993;13:240–6.
31. Zaiou M, Visvikis S, Gueguen R, Parra HJ, Fruchart JC, Siest G.
DNA polymorphisms of human apolipoprotein A-IV gene: frequency
and effects on lipid, lipoprotein and apolipoprotein levels in a French
population. Clin Genet 1994;46:248–54.
32. Von Eckardstein A, Funke H, Schulte M, Erren M, Schulte H,
Assmann G. Nonsynonymous polymorphic sites in the apolipoprotein
(apo) A-IV gene are associated with changes in the concentration of
apo B- and apo A-I-containing lipoproteins in a normal population.
Am J Hum Genet 1992;50:1115–28.
33. Kamboh MI, Friedlaender JS, Ahn YI, Ferrell RE. A common
deletion polymorphism in the apolipoprotein A4 gene and its signif-
icance in lipid metabolism. Arterioscler Thromb 1994;14:656–62.
34. Nowicka G, Bruning T, Bottcher A, Kahl G, Schmitz G. Macrophage
interaction of HDL subclasses separated by free flow isotachophoresis.
J Lipid Res 1990;31:1947–63.
35. Qin XF, Swertfeger DK, Zheng SQ, Hui DY, Tso P. Apolipoprotein
A-IV: a potent endogenous inhibitor of lipid oxidation. Am J Physiol
1998;274:H1836–40.
36. Schaefer EJ, Brousseau ME. Diet, lipoproteins and coronary heart
disease. Endocrinol Metab Clin North Am 1998;27:711–32.
757JACC Vol. 36, No. 3, 2000 Kronenberg et al.
September 2000:751–7 ApoA-IV and CAD
